Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series

Femin Prasad; Riddhita De; Vittal Korann; Araba F. Chintoh; Gary Remington; Bjørn H. Ebdrup; Dan Siskind; Filip Krag Knop; Tina Vilsbøll; Anders Fink-Jensen; Margaret K. Hahn; Sri Mahavir Agarwal

doi:10.1177/20451253231165169

Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series

Femin Prasad, Riddhita De, Vittal Korann, Araba F. Chintoh, Gary Remington, Bjørn H. Ebdrup, Dan Siskind, Filip Krag Knop, Tina Vilsbøll, Anders Fink-Jensen, Margaret K. Hahn, Sri Mahavir Agarwal

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

15 Citationer (Scopus)

18 Downloads (Pure)

Abstract

Metformin is the currently accepted first-line treatment for antipsychotic-associated weight gain (AAWG). However, not all patients benefit from metformin. Glucagon-like peptide-1 receptor agonists (GLP1-RA) have shown promise in the management of obesity in the general population, with preliminary evidence supporting efficacy in AAWG. Semaglutide is a weekly injectable GLP-1RA which received recent approval for obesity management and noted superiority over other GLP-1RAs. This study explored the efficacy and tolerability of semaglutide in AAWG among individuals with severe mental illness. A retrospective chart review of patients treated with semaglutide in the Metabolic Clinic at the Center for Addiction and Mental Health (CAMH) between 2019 and 2021 was conducted. Patients failing a trial of metformin (

Originalsprog	Engelsk
Artikelnummer	20451253231165169
Tidsskrift	Therapeutic Advances in Psychopharmacology
Vol/bind	13
Antal sider	10
ISSN	2045-1253
DOI	https://doi.org/10.1177/20451253231165169
Status	Udgivet - 2023

Bibliografisk note

Corrigendum: https://journals.sagepub.com/doi/10.1177/20451253241258536

Adgang til dokumentet

10.1177/20451253231165169Licens: CC BY-NC

FulltextForlagets udgivne version, 510 KBLicens: CC BY-NC

Citationsformater

Prasad, F., De, R., Korann, V., Chintoh, A. F., Remington, G., Ebdrup, B. H., Siskind, D., Knop, F. K., Vilsbøll, T., Fink-Jensen, A., Hahn, M. K., & Agarwal, S. M. (2023). Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series. Therapeutic Advances in Psychopharmacology, 13, [20451253231165169]. https://doi.org/10.1177/20451253231165169

Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series. / Prasad, Femin; De, Riddhita; Korann, Vittal; Chintoh, Araba F.; Remington, Gary; Ebdrup, Bjørn H.; Siskind, Dan; Knop, Filip Krag ; Vilsbøll, Tina ; Fink-Jensen, Anders; Hahn, Margaret K.; Agarwal, Sri Mahavir.

I: Therapeutic Advances in Psychopharmacology, Bind 13, 20451253231165169, 2023.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Prasad, F, De, R, Korann, V, Chintoh, AF, Remington, G, Ebdrup, BH, Siskind, D, Knop, FK , Vilsbøll, T , Fink-Jensen, A, Hahn, MK & Agarwal, SM 2023, 'Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series', Therapeutic Advances in Psychopharmacology, bind 13, 20451253231165169. https://doi.org/10.1177/20451253231165169

Prasad, Femin ; De, Riddhita ; Korann, Vittal ; Chintoh, Araba F. ; Remington, Gary ; Ebdrup, Bjørn H. ; Siskind, Dan ; Knop, Filip Krag ; Vilsbøll, Tina ; Fink-Jensen, Anders ; Hahn, Margaret K. ; Agarwal, Sri Mahavir. / Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series. I: Therapeutic Advances in Psychopharmacology. 2023 ; Bind 13.

@article{9e81be9347e340be802edd308a69a9dc,

title = "Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series",

abstract = "Metformin is the currently accepted first-line treatment for antipsychotic-associated weight gain (AAWG). However, not all patients benefit from metformin. Glucagon-like peptide-1 receptor agonists (GLP1-RA) have shown promise in the management of obesity in the general population, with preliminary evidence supporting efficacy in AAWG. Semaglutide is a weekly injectable GLP-1RA which received recent approval for obesity management and noted superiority over other GLP-1RAs. This study explored the efficacy and tolerability of semaglutide in AAWG among individuals with severe mental illness. A retrospective chart review of patients treated with semaglutide in the Metabolic Clinic at the Center for Addiction and Mental Health (CAMH) between 2019 and 2021 was conducted. Patients failing a trial of metformin (",

keywords = "antipsychotics, metformin, obesity, semaglutide, severe mental illness, ONCE-WEEKLY SEMAGLUTIDE, PHASE 3A, OPEN-LABEL, DOUBLE-BLIND, ADD-ON, JAPANESE PATIENTS, DAILY SITAGLIPTIN, ORAL SEMAGLUTIDE, DIABETES CARE, DOUBLE-DUMMY",

author = "Femin Prasad and Riddhita De and Vittal Korann and Chintoh, {Araba F.} and Gary Remington and Ebdrup, {Bj{\o}rn H.} and Dan Siskind and Knop, {Filip Krag} and Tina Vilsb{\o}ll and Anders Fink-Jensen and Hahn, {Margaret K.} and Agarwal, {Sri Mahavir}",

note = "Corrigendum: https://journals.sagepub.com/doi/10.1177/20451253241258536",

year = "2023",

doi = "10.1177/20451253231165169",

language = "English",

volume = "13",

journal = "Therapeutic Advances in Psychopharmacology",

issn = "2045-1253",

publisher = "SAGE Publications",

}

TY - JOUR

T1 - Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series

AU - Prasad, Femin

AU - De, Riddhita

AU - Korann, Vittal

AU - Chintoh, Araba F.

AU - Remington, Gary

AU - Ebdrup, Bjørn H.

AU - Siskind, Dan

AU - Knop, Filip Krag

AU - Vilsbøll, Tina

AU - Fink-Jensen, Anders

AU - Hahn, Margaret K.

AU - Agarwal, Sri Mahavir

N1 - Corrigendum: https://journals.sagepub.com/doi/10.1177/20451253241258536

PY - 2023

Y1 - 2023

N2 - Metformin is the currently accepted first-line treatment for antipsychotic-associated weight gain (AAWG). However, not all patients benefit from metformin. Glucagon-like peptide-1 receptor agonists (GLP1-RA) have shown promise in the management of obesity in the general population, with preliminary evidence supporting efficacy in AAWG. Semaglutide is a weekly injectable GLP-1RA which received recent approval for obesity management and noted superiority over other GLP-1RAs. This study explored the efficacy and tolerability of semaglutide in AAWG among individuals with severe mental illness. A retrospective chart review of patients treated with semaglutide in the Metabolic Clinic at the Center for Addiction and Mental Health (CAMH) between 2019 and 2021 was conducted. Patients failing a trial of metformin (

AB - Metformin is the currently accepted first-line treatment for antipsychotic-associated weight gain (AAWG). However, not all patients benefit from metformin. Glucagon-like peptide-1 receptor agonists (GLP1-RA) have shown promise in the management of obesity in the general population, with preliminary evidence supporting efficacy in AAWG. Semaglutide is a weekly injectable GLP-1RA which received recent approval for obesity management and noted superiority over other GLP-1RAs. This study explored the efficacy and tolerability of semaglutide in AAWG among individuals with severe mental illness. A retrospective chart review of patients treated with semaglutide in the Metabolic Clinic at the Center for Addiction and Mental Health (CAMH) between 2019 and 2021 was conducted. Patients failing a trial of metformin (

KW - antipsychotics

KW - metformin

KW - obesity

KW - semaglutide

KW - severe mental illness

KW - ONCE-WEEKLY SEMAGLUTIDE

KW - PHASE 3A

KW - OPEN-LABEL

KW - DOUBLE-BLIND

KW - ADD-ON

KW - JAPANESE PATIENTS

KW - DAILY SITAGLIPTIN

KW - ORAL SEMAGLUTIDE

KW - DIABETES CARE

KW - DOUBLE-DUMMY

U2 - 10.1177/20451253231165169

DO - 10.1177/20451253231165169

M3 - Journal article

C2 - 37113745

VL - 13

JO - Therapeutic Advances in Psychopharmacology

JF - Therapeutic Advances in Psychopharmacology

SN - 2045-1253

M1 - 20451253231165169

ER -